Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences.

Register
Cart (0)

Home > References > 2012 > Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences.

Contact an Account Manager

Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences.

Pinches M, Betts C, Bickerton S, Burdett L, Thomas H, Derbyshire N, Jones HB, Moores M.

Journal		Toxicol Pathol.
Species
Analytes Measured		Albumin , GSTYb1 , HAVCR1 KIM-1 , Osteopontin , RPA-1
Matrix Tested		Urine

Year		2012
Volume		40
Page Numbers		522-533
Application		Toxicology

Abstract

A number of novel urinary biomarkers have been identified and partially qualified for use as markers for renal injury in rats. We use two novel multiplex assays to quantify biomarker concentration in multiple urine collections made prior to and following administration of cisplatin, a common nephrotoxicant, to rats. We investigate the correlation of the magnitude of biomarker changes with the severity of histopathological observations and explore the relationship of these to both dose and sex. The novel biomarkers evaluated are urinary albumin, alpha glutathione s-transferase (α-GST), glutathione S-transferase-yb1 (GSTYb1), lipocalin-2, kidney injury molecule-1 (KIM-1), osteopontin, and renal papillary antigen 1 (RPA-1) and plasma cystatin C, alongside the traditional biomarkers of plasma urea, creatinine, and urinary n-acetyl-beta-d-glucosaminidase (NAG), total protein, and glucose. We show for all time points, and for almost all doses, that male rats consistently had either more severely graded or a higher incidence of histologically observed lesions than females; that changes in urinary glucose, total urinary protein, NAG, and the novel urinary biomarkers albumin, osteopontin, and KIM-1 are clearly temporally associated; and that changes are related to the severity of injury. We also found that receiver operating characteristic curve analysis and area under the curve are significantly higher than urea or creatinine for all new biomarkers except aGST, GSTYb1, cystatin c, and total protein in both sexes.

View Publications

Related Products


U-PLEX Human HAVCR1/KIM-1 Antibody Set HAVCR1/KIM-1 \| Human
U-PLEX Human HAVCR1/KIM-1 Assay, 384-well HAVCR1/KIM-1 \| Human Singleplex
U-PLEX Human HAVCR1/KIM-1 Assay HAVCR1/KIM-1 \| Human Singleplex
R-PLEX Mouse HAVCR1/KIM-1 Antibody Set HAVCR1/KIM-1 \| Mouse
R-PLEX Mouse HAVCR1/KIM-1 Assay HAVCR1/KIM-1 \| Mouse Singleplex
R-PLEX Rat Albumin Antibody Set Albumin \| Rat
R-PLEX Human Albumin Assay Albumin \| Human Singleplex
R-PLEX Rat Osteopontin Assay Osteopontin \| Rat Singleplex
R-PLEX Rat Albumin Assay Albumin \| Rat Singleplex
R-PLEX Human Osteopontin Assay Osteopontin \| Human Singleplex
R-PLEX Rat HAVCR1/KIM-1 Assay HAVCR1/KIM-1 \| Rat Singleplex
R-PLEX Human Albumin Antibody Set Albumin \| Human
R-PLEX Rat Osteopontin Antibody Set Osteopontin \| Rat
R-PLEX Rat HAVCR1/KIM-1 Antibody Set HAVCR1/KIM-1 \| Rat
R-PLEX Human Osteopontin Antibody Set Osteopontin \| Human
Kidney Injury Panel 3 Human Kit Calbindin, Clusterin, HAVCR1/KIM-1, Osteoactivin, TFF3, VEGF-A \| Human Multiplex
Kidney Injury Panel 1 Rat Kit Albumin, HAVCR1/KIM-1, NGAL/LCN2, Osteopontin \| Rat Multiplex
U-PLEX Immuno-Oncology Group 1 (human) Assays APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, Galectin-9, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOS-L/B7-H2, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L1 (epitope 2), PD-L2, Pentraxin 3, Perforin, PlGF, proMMP-9, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40 \| Human Multiplex
U-PLEX Immuno-Oncology Group 1 (human) Assays APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, Galectin-9, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOS-L/B7-H2, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L1 (epitope 2), PD-L2, Pentraxin 3, Perforin, PlGF, proMMP-9, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40 \| Human Multiplex
U-PLEX Immuno-Oncology Group 1 (human) 384-well Assays BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF (basic), FLT3L, Fractalkine, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-5, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L2, PlGF, RANKL/TNFSF11, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, YKL-40 \| Human Multiplex

R-PLEX: Matched Antibody Sets - Suitable for Many Research Applications

Quick Links

Browse Our Products

By Analytes

By Applications

Contact Information

Customer Service/Orders
1-240-314-2795

5:00 a.m. to 8:00 p.m.
US Eastern Time

Email

Scientific/Technical Support
1-240-314-2798

5:30 a.m. to 5:30 p.m.
US Eastern Time

Email

Instrument Support
1-301-947-2057

8:30 a.m. - 5:30 p.m.
US Eastern Time

Email

Company Headquarters
1-240-314-2600
1601 Research Blvd.
Rockville, Maryland 20850-3173
USA


U-PLEX Human HAVCR1/KIM-1 Antibody Set HAVCR1/KIM-1 \| Human
U-PLEX Human HAVCR1/KIM-1 Assay, 384-well HAVCR1/KIM-1 \| Human Singleplex
U-PLEX Human HAVCR1/KIM-1 Assay HAVCR1/KIM-1 \| Human Singleplex
R-PLEX Mouse HAVCR1/KIM-1 Antibody Set HAVCR1/KIM-1 \| Mouse
R-PLEX Mouse HAVCR1/KIM-1 Assay HAVCR1/KIM-1 \| Mouse Singleplex
R-PLEX Rat Albumin Antibody Set Albumin \| Rat
R-PLEX Human Albumin Assay Albumin \| Human Singleplex
R-PLEX Rat Osteopontin Assay Osteopontin \| Rat Singleplex
R-PLEX Rat Albumin Assay Albumin \| Rat Singleplex
R-PLEX Human Osteopontin Assay Osteopontin \| Human Singleplex
R-PLEX Rat HAVCR1/KIM-1 Assay HAVCR1/KIM-1 \| Rat Singleplex
R-PLEX Human Albumin Antibody Set Albumin \| Human
R-PLEX Rat Osteopontin Antibody Set Osteopontin \| Rat
R-PLEX Rat HAVCR1/KIM-1 Antibody Set HAVCR1/KIM-1 \| Rat
R-PLEX Human Osteopontin Antibody Set Osteopontin \| Human
Kidney Injury Panel 3 Human Kit Calbindin, Clusterin, HAVCR1/KIM-1, Osteoactivin, TFF3, VEGF-A \| Human Multiplex
Kidney Injury Panel 1 Rat Kit Albumin, HAVCR1/KIM-1, NGAL/LCN2, Osteopontin \| Rat Multiplex
U-PLEX Immuno-Oncology Group 1 (human) Assays APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, Galectin-9, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOS-L/B7-H2, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L1 (epitope 2), PD-L2, Pentraxin 3, Perforin, PlGF, proMMP-9, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40 \| Human Multiplex
U-PLEX Immuno-Oncology Group 1 (human) Assays APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, Galectin-9, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOS-L/B7-H2, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1α, MIP-1β, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9 (total), Nectin-4, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L1 (epitope 2), PD-L2, Pentraxin 3, Perforin, PlGF, proMMP-9, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TNF-RI, TNF-RII, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Flt-1, YKL-40 \| Human Multiplex
U-PLEX Immuno-Oncology Group 1 (human) 384-well Assays BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD28, CD40L (soluble), CD276/B7-H3, CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, FGF (basic), FLT3L, Fractalkine, G-CSF, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GRO-α, HAVCR2/TIM-3, I-309, IFN-α2a, IFN-β, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-2Rα, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL-25, IL-17F, IL-18, IL-21, IL-22, IL-23, IL-27, IL-29/IFN-λ1, IL-31, IL-33, IP-10, I-TAC, LAG3, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-5, OX40/TNFRSF4, PD1 (epitope 1), PD1 (epitope 2), PD-L1 (epitope 1), PD-L2, PlGF, RANKL/TNFSF11, Tie-2, TIGIT, TLR1, TNF-α, TNF-β, TPO, TRAIL, TSLP, VEGF-A, VEGF-D, YKL-40 \| Human Multiplex

Please Sign In

User name

Password

Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences.

Abstract

Related Products

Quick Links

Browse Our Products

Contact Information

Products

Services

Orders & Support

Key Topics